Ann: Dimerix Presents at ASX Small & Mid-Cap Conference, page-55

You quote: "sparsentan and irbesartan had similar safety profiles, and the frequency of adverse events was similar in the two groups”

Yes - and they were similarly bad:

"In terms of safety, the rate of serious, treatment-related adverse events was similar between the two groups (37% in the sparsentan group and 43.9% in the irbesartan group). Although there were more episodes of hyperkalemia (16.8% vs. 10.7%) and hypotension (17.9% vs. 11.2%) in the sparsentan group, there was no increased risk of peripheral edema (19.6% vs. 21.9%)"

https://www.theisn.org/blog/2024/02...trial-new-selection-of-global-trials-out-now/